You are here: Introduction > Clinical particulars
Quantum Cat FeLV:  Clinical particulars
Quantum Cat FeLV
Quantum Cat FeLV
Clinical particulars
Target species
Cats from 9 weeks of age.
Indications for use
Active immunization of cats to reduce persistent viraemia and lymphoid tumours caused by FeLV infection, and thereby to reduce other diseases associated with FeLV infection. Onset of immunity occurs by approximately 3 weeks after the last dose of the Basic Vaccination Scheme. The duration of immunity is at least 12 months.
Do not use in unhealthy animals. The use of immunosuppressant drugs or procedures within one month of vaccination is contra-indicated.
Special warnings for each target species
If an anaphylactic reaction occurs, institute treatment according to the clinical signs using adrenaline or other appropriate medication. Vaccination is of no known clinical value in cats with pre-existing FeLV infection, nor will it change the natural course of the disease. The effect of maternally derived antibodies (MDA) on the response to vaccination is not known, but on the basis of published data and field use it is expected that the levels of MDA that will be present at 9 weeks of age will not interfere with the response to vaccination.
Special precautions for use
User warnings: In case of accidental self-injection, wash the area immediately with water. If symptoms develop, seek medical attention showing a copy of the product literature.
Adverse reactions
On very rare occasions, soft painless swellings (<1 cm average) may occur after vaccination, which may be evident as painless hard nodules for up to 21 days. Transient increases in rectal temperature for up to 48 hours may also be observed. A small proportion of cats may show reduced activity for 1 or 2 days after vaccination and pain on injection (generally slight) may be observed. Rare occurrences of anaphylaxis, and gastro-enteric signs (emesis and diarrhoea) have been reported after vaccination. When Quantum Cat FeLV and Quantum Cat CVRP are administered simultaneously, incidence of local reactions may be increased.
Use during pregnancy, lactation or lay
Do not use during pregnancy.
Safety and efficacy data are available which demonstrate that this vaccine can be mixed with Quantum Cat CVRP. No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the product listed above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
Amounts to be administered and administration route
Shake the vial well immediately before use, and administer the entire contents (1 ml) by subcutaneous injection. Basic vaccination: In cats aged 9 weeks and more, two doses should be given, with an interval of 3-4 weeks. If simultaneous immunisation against feline infectious enteritis (panleucopaenia) and respiratory disease due to feline viral rhinotracheitis (FVR) virus and calicivirus is required, Quantum Cat FeLV can be used in place of the diluent to reconstitute Quantum Cat CVRP (freeze-dried feline infectious enteritis, viral rhinotracheitis and calicivirus vaccine, living), using the reconstitution method described in the product information for Quantum Cat CVRP. Once mixed, the vaccines should be injected immediately via the subcutaneous route.
Re-vaccination Annual booster vaccination is recommended.
No reactions other than those listed in Section “Adverse reactions” are observed after an overdose administration.
Withdrawal periods
Not applicable.
  Date updated: 2 October 2013